BioGrad Leads £6 Million Worth PCR Machine Donation to Strengthen UK Science Education

BioGrad is spearheading efforts to place £10.5 million worth of donated PCR equipment by the end of 2025, with £6 million already delivered across the UK.

ThirdLaw Molecular Rebrands as Ladder Bio; Announces $5.5M Seed Financing Led by Medical Excellence Capital and Appoints Eric Heil as Chief Executive Officer

ThirdLaw Molecular, Inc. today announced its new name change, Ladder Bio Inc., reflecting the company’s mission to pioneer Spiroligomer™ therapeutics (“ladder-shaped peptide-like molecules”), a novel therapeutic modality for new medicines. The company name change follows the closing of a $5.5 million Series Seed financing led by Medical Excellence Capital, with participation from Hatch BioFund. The company also announced the appointment of Eric Heil as Chief Executive Officer and the election of David Scheer and Brian Halak, PhD to its Board of Directors.

Advarra and IgniteData announce partnership to simplify clinical trial data transfer for research sites

IgniteData’s Archer platform will connect the site’s EHR system, Advarra’s eSource and EDC systems, and the sponsor’s EDC system of choice, ensuring compatibility between solutions from different vendors.

Integrated DNA Technologies and Beckman Coulter Life Sciences Partner to Advance Cancer Research Through Automated NGS Workflows

Collaboration aims to equip users with complete NGS solution from sample to answer

CluePoints Data and Knowledge Manager Appointed to ACT Editorial Advisory Board

CluePoints, provider of leading statistical and AI-driven software solutions, has announced Sylviane de Viron, its Data and Knowledge Manager, has been appointed to the Applied Clinical Trials (ACT) editorial advisory board.

Abselion Launches His-tagged Protein Quantification Kit and Sensors for Amperia at PEGS Europe 2025

* Ready-to-use solution, developed in collaboration with GenScript, offers rapid and reliable quantification of His-tagged proteins * Broadens Amperia’s applications across recombinant protein research, screening, and development * Abselion to showcase kit alongside Amperia platform at PEGS Europe in Lisbon, Portugal from 11–13 November

MadeAi™ Unveils New Capabilities for GVD and JCA Reporting, Setting a New Benchmark for Life Science GenAI-Enabled Evidence Synthesis and Reporting

MadeAi launched new capabilities in its MadeAi(TM) GenAI-powered platform for life science evidence synthesis and report generation - capabilities that expedite global value dossier (GVD) and Joint Clinical Assessment (JCA), and streamline literature review from protocol creation to regulatory-ready reporting.

SPT Labtech and Alithea Genomics Collaborate to Automate Ultra Sensitive Single-Cell Transcriptomic Workflows

Abzena and Mabqi Announce Strategic Partnership to Offer Integrated Discovery through Development Solution

Nuclera expands access to eProtein Discovery for APAC customers with distributor agreement in Australia and New Zealand

Partnership with Solve Scientific strengthens international sales as part of ongoing global expansion

DoseMe Acquires Firstline to Build End-to-End Clinical Decision Support for Health Systems in the Global Fight Against Infectious Disease

DoseMe, a global leader in model-informed precision dosing (MIPD) software and a portfolio company of Fairlong Capital, today announced the acquisition of Firstline, a leading clinical decision support platform utilized worldwide. Firstline enables clinicians to rapidly access local, evidence-based infectious disease treatment guidance, susceptibility patterns, and antimicrobial stewardship (AMS) resources. The combination of DoseMe and Firstline creates a single, connected experience from therapy selection through personalized dosing, giving clinicians a faster path to optimal care.

Ambience Healthcare Launches AI-Powered “Conditions Advisor” to Support Comprehensive Inpatient Documentation and High-Quality Care

Aylward Enterprises Highlights TCM Tablet Counter with 100% Count Verification and On-the-Fly Rejection

Aylward Enterprises, a recognized leader in oral solid dose (OSD) packaging automation, highlights the TCM Tablet Counter, engineered to provide 100% count verification and reject-on-the-fly performance for pharmaceutical, nutraceutical, and healthcare packaging lines.

Lonza to Expand Bioscience Testing Offering With the Acquisition of Redberry

Lonza has announced that it has signed an agreement to acquire Redberry.

EazeBio and UC Santa Cruz Announce Strategic Partnership to Advance Instrument-Free Diagnostic Platform

EazeBio has announced a strategic partnership with the University of California, Santa Cruz to advance and commercialize a groundbreaking instrument-free diagnostic platform.

Grass America Highlights Its Institutional Hinges Designed for Healthcare Facilities

Spaarne Gasthuis to Advance its Commitment to Patient Care with Proscia’s Software

Spaarne Gasthuis, a top clinical teaching hospital serving part of the Greater Amsterdam region, is fully digitizing its pathology practice with Concentriq® AP-Dx* from Proscia®. With this software platform, the hospital will empower its pathologists to play an even more significant role in guiding personalized treatment decisions for hundreds of thousands of patients each year.

Leading Global Cancer Center to Integrate Triomics AI Platform to Improve Clinical Trial Screening

Leading Global Cancer Center to Integrate Triomics AI Platform to Improve Clinical Trial Screening

Elixion Biotech validates its quantum-informed R&D process, proving readiness to advance precision medicines

Elixion Biotech has emerged from stealth with a breakthrough that could reshape early-stage drug discovery. In just eleven months, and without external funding, the Zurich-based therapeutics company has validated its quantum physics-informed R&D process, confirming its ability to accurately predict and identify novel drug targets. The milestone positions Elixion to advance its precision-oncology pipeline and opens the door to seed-stage investment.

Orion and Abzena Announce Exclusive Commercial License for Abzena’s Antibody